{"id":"buprenorphine-experimental","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Constipation"},{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Headache"},{"rate":"10-20","effect":"Dizziness"},{"rate":"10-15","effect":"Sweating"},{"rate":"<5","effect":"Respiratory depression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Buprenorphine's partial agonist activity at the mu-opioid receptor produces a ceiling effect on respiratory depression, making it safer than full opioid agonists. It is used primarily for pain management and opioid use disorder treatment, where its high receptor binding affinity and long duration of action allow for once-daily or less frequent dosing while minimizing withdrawal symptoms and overdose risk.","oneSentence":"Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the central nervous system, producing analgesia and reducing opioid cravings.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:41:12.715Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe acute and chronic pain"},{"name":"Opioid use disorder (maintenance treatment)"}]},"trialDetails":[{"nctId":"NCT07435077","phase":"PHASE4","title":"Examining Analgesic Synergy and Efficacy in Trauma Care","status":"NOT_YET_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2026-05","conditions":"Opioid Use Disorder","enrollment":282},{"nctId":"NCT07498322","phase":"NA","title":"Chicago Data-driven Opioid Use Disorder Screening, Engagement, Treatment and Planning System","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2026-06-01","conditions":"Opiod Use Disorder","enrollment":271031},{"nctId":"NCT04677114","phase":"PHASE2","title":"Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections","status":"COMPLETED","sponsor":"Laura Fanucchi","startDate":"2021-03-16","conditions":"Drug Use, Opioid-use Disorder","enrollment":71},{"nctId":"NCT06496230","phase":"EARLY_PHASE1","title":"Open Trial of Technology-Enhanced Behavioral Intervention for Buprenorphine Retention in Pregnant and Postpartum People","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2024-08-06","conditions":"Opioid Use Disorder, Pregnancy Related","enrollment":15},{"nctId":"NCT06441604","phase":"PHASE2","title":"Extended-release Buprenorphine as a Novel Low-dose Induction Strategy","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2025-10-27","conditions":"Opioid Use Disorder","enrollment":30},{"nctId":"NCT07149870","phase":"NA","title":"Pain Management Teams Using Whole Health to Optimize Function and Safety in Veterans: The TEAMWORK Trial","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2025-11-20","conditions":"Chronic Pain","enrollment":432},{"nctId":"NCT06651177","phase":"PHASE2","title":"Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder","status":"RECRUITING","sponsor":"T. John Winhusen, PhD","startDate":"2026-01-29","conditions":"Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe","enrollment":310},{"nctId":"NCT07485335","phase":"PHASE4","title":"A Bundled Intervention - Phase 2","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-09-07","conditions":"Opioid Use Disorder, Opioid Overdose","enrollment":160},{"nctId":"NCT06157840","phase":"NA","title":"Development of an mHealth Behavioral Sleep Medicine Intervention for Use During Medication Assisted Treatment for MOUD","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2025-08-25","conditions":"Opioid Use Disorder, Poor Quality Sleep","enrollment":40},{"nctId":"NCT06576843","phase":"PHASE2","title":"INDV-6001 Multiple-Dose Pharmacokinetic Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2024-09-17","conditions":"Moderate to Severe Opioid Use Disorder","enrollment":123},{"nctId":"NCT07469501","phase":"PHASE4","title":"Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-06","conditions":"Opioid Use Disorder, Fentanyl","enrollment":50},{"nctId":"NCT05722561","phase":"PHASE2","title":"E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2024-08-08","conditions":"Opioid Use Disorder, Cigarette Smoking","enrollment":302},{"nctId":"NCT07278518","phase":"NA","title":"Evaluation of a Patient Decision Aid for Emergency Department Initiated Buprenorphine","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2026-05-19","conditions":"Opioid Use Disorder","enrollment":20},{"nctId":"NCT06784180","phase":"PHASE4","title":"Intrathecal Hydromorphone vs Intrathecal Morphine to Treat Post Cesarean Pain in Patients With Opioid Use Disorder Taking Buprenorphine","status":"WITHDRAWN","sponsor":"University of North Carolina, Chapel Hill","startDate":"2026-02","conditions":"Opioid Use Disorder","enrollment":""},{"nctId":"NCT06341608","phase":"NA","title":"Improving Access to Opioid Use Disorder Treatment Among Marginalized Patients With a Tailored Telehealth Intervention","status":"NOT_YET_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-04-15","conditions":"Opioid Use Disorder","enrollment":60},{"nctId":"NCT06948890","phase":"NA","title":"Effect of Music on Cue Reactivity for Patients With Opioid Use Disorder","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2025-04-20","conditions":"Opioid Use Disorder","enrollment":28},{"nctId":"NCT06367387","phase":"PHASE4","title":"Pain Self-Management and Patient-Oriented Dosing for Pain and in Retention Opioid Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Erin Winstanley","startDate":"2024-05-28","conditions":"Opioid Use Disorder, Chronic Pain","enrollment":268},{"nctId":"NCT07420283","phase":"PHASE2","title":"A Study of Brenipatide in Participants With Opioid Use Disorder","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-02-13","conditions":"Opioid Use Disorder","enrollment":465},{"nctId":"NCT06726200","phase":"EARLY_PHASE1","title":"A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use","status":"RECRUITING","sponsor":"Rachel R. Luba","startDate":"2026-08","conditions":"Opioid Use Disorder","enrollment":60},{"nctId":"NCT06628622","phase":"PHASE1","title":"A Study to Test Whether BI 1356225 Improves Impulsive Behavior in People With Opioid Use Disorder Who Are Taking Buprenorphine","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2025-01-27","conditions":"Opioid Use Disorder","enrollment":60},{"nctId":"NCT02345655","phase":"NA","title":"On-site Evaluation of Substances Consumption on Opiate Maintenance","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2016-04-11","conditions":"Opiate Addiction","enrollment":42},{"nctId":"NCT07439549","phase":"PHASE4","title":"Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial","status":"NOT_YET_RECRUITING","sponsor":"Pouya Azar","startDate":"2026-02-18","conditions":"Opioid Use Disorder","enrollment":12},{"nctId":"NCT07434427","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Intravenous Buprenorphine Administered Via PCA System Versus Oxycodone in the Management of Postoperative Pain After Video-Assisted Thoracoscopic Surgery","status":"NOT_YET_RECRUITING","sponsor":"Medical University of Silesia","startDate":"2026-02","conditions":"Acute Postoperative Pain, Chronic Postoperative Pain, Toracosurgery","enrollment":200},{"nctId":"NCT07430345","phase":"PHASE1, PHASE2","title":"Buprenorphine for Analgesia in Older Adults With Acute Fractures in the Emergency Department: a Randomized Controlled Study","status":"NOT_YET_RECRUITING","sponsor":"The Cooper Health System","startDate":"2026-04","conditions":"Fracture","enrollment":48},{"nctId":"NCT07178158","phase":"NA","title":"Enhancing Addiction Treatment Through Psychoeducation","status":"NOT_YET_RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2026-05-01","conditions":"Substance Use Disorders","enrollment":40},{"nctId":"NCT06593093","phase":"PHASE1, PHASE2","title":"A Bundled Intervention","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-02-13","conditions":"Opioid Use Disorder, Opioid Overdose","enrollment":190},{"nctId":"NCT06005662","phase":"PHASE2","title":"Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2027-04","conditions":"Opioid Use Disorder","enrollment":""},{"nctId":"NCT05991622","phase":"PHASE2","title":"Combined Injectable Treatment for HIV and OUD","status":"WITHDRAWN","sponsor":"Rhode Island Hospital","startDate":"2022-04-01","conditions":"Human Immunodeficiency Virus, Opioid Use Disorder","enrollment":""},{"nctId":"NCT06854029","phase":"PHASE4","title":"NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings","status":"NOT_YET_RECRUITING","sponsor":"Duke University","startDate":"2026-06","conditions":"HIV Infections, Opioid Use Disorder, Incarceration; Lens","enrollment":300},{"nctId":"NCT04245423","phase":"NA","title":"The Whole Health Study: Collaborative Care for OUD and Mental Health Conditions","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2020-12-15","conditions":"Opioid-use Disorder, Mental Health Conditions","enrollment":567},{"nctId":"NCT04276259","phase":"PHASE4","title":"Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses","status":"COMPLETED","sponsor":"Marta Peciña, MD PhD","startDate":"2020-10-19","conditions":"Major Depressive Disorder, Depression","enrollment":120},{"nctId":"NCT07148206","phase":"PHASE3","title":"Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial","status":"NOT_YET_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-05","conditions":"Opioid Use Disorder","enrollment":40},{"nctId":"NCT07044466","phase":"NA","title":"Social Functioning in Opioid Use Disorder","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2026-02-23","conditions":"Opioid Use Disorder","enrollment":230},{"nctId":"NCT04995029","phase":"PHASE4","title":"Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2021-10-26","conditions":"Moderate to Severe Opioid-use Disorder","enrollment":785},{"nctId":"NCT06102200","phase":"NA","title":"An Integrated Intervention Involving Recovery Coaching and Cognitive Behavioral Therapy for Opioid Use Disorder","status":"COMPLETED","sponsor":"Prisma Health-Upstate","startDate":"2023-10-05","conditions":"Standard of Care, Standard of Care + CBT4CBT, Standard of Care + CBT4CBT + RC","enrollment":92},{"nctId":"NCT07176351","phase":"PHASE4","title":"Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-03","conditions":"Opioid Use Disorder","enrollment":60},{"nctId":"NCT05051644","phase":"PHASE1","title":"An Adaptive Walking Intervention to Manage Chronic Pain in Veterans With Opioid Use Disorder Engaged in Opioid Agonist Treatment","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2022-04-01","conditions":"Opioid Use Disorder, Chronic Pain","enrollment":60},{"nctId":"NCT03616236","phase":"PHASE3","title":"Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment","status":"SUSPENDED","sponsor":"Friends Research Institute, Inc.","startDate":"2022-07-01","conditions":"Opioid Use","enrollment":320},{"nctId":"NCT06306443","phase":"PHASE3","title":"Buprenorphine for Individuals in Jail","status":"RECRUITING","sponsor":"Friends Research Institute, Inc.","startDate":"2025-07-01","conditions":"Opioid Use Disorder","enrollment":240},{"nctId":"NCT05333341","phase":"NA","title":"Pain Care at Home to Amplify Function (Pain CHAMP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2023-06-16","conditions":"Opioid Use Disorder, Opioid Misuse, Chronic Pain","enrollment":259},{"nctId":"NCT07361432","phase":"PHASE3","title":"Digital Treatment for Chronic Pain and Addiction in Veterans With Opioid Use Disorder Receiving Buprenorphine","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-11-02","conditions":"Opioid Use Disorder, Chronic Pain","enrollment":250},{"nctId":"NCT04408313","phase":"PHASE2, PHASE3","title":"Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail","status":"ACTIVE_NOT_RECRUITING","sponsor":"Friends Research Institute, Inc.","startDate":"2020-10-28","conditions":"Opioid-use Disorder","enrollment":240},{"nctId":"NCT05063201","phase":"PHASE2","title":"Cariprazine for Comorbid Cocaine and Opioid Use Disorder","status":"COMPLETED","sponsor":"Kyle Kampman","startDate":"2022-08-05","conditions":"Opioid-use Disorder, Cocaine Use Disorder","enrollment":26},{"nctId":"NCT07342504","phase":"NA","title":"Better Experiences in Substance Treatment: A Brief Alcohol-focused Intervention Tailored for Patients in Opioid Agonist Treatment","status":"RECRUITING","sponsor":"University of Notre Dame","startDate":"2026-01-21","conditions":"Alcohol Use Disorder, Opioid Use Disorder, Alcohol Use","enrollment":60},{"nctId":"NCT07001371","phase":"NA","title":"Emotional Brain Training for Addiction Medicine Treatment - A Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"Loma Linda University","startDate":"2026-03","conditions":"Cannabis Use Disorder, Stimulant Use Disorder, Opioid Use Disorder","enrollment":54},{"nctId":"NCT04601064","phase":"NA","title":"Peer Supported Collaborative Care Mental Health and Substance Use Disorder Care","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2022-04-20","conditions":"HIV Infections, Substance Use Disorders, Mental Health Disorder","enrollment":405},{"nctId":"NCT05988710","phase":"PHASE4","title":"Low-dose Buccal Buprenorphine: Relative Abuse Potential and Analgesia","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2023-10-19","conditions":"Analgesia, Abuse Opioids, Pain","enrollment":120},{"nctId":"NCT04375033","phase":"PHASE4","title":"A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2020-11-03","conditions":"Opioid Use Disorder","enrollment":952},{"nctId":"NCT03698669","phase":"NA","title":"Treating Chronic Pain in Buprenorphine Patients in Primary Care Settings","status":"COMPLETED","sponsor":"Boston University","startDate":"2019-08-21","conditions":"Opioid-Related Disorders","enrollment":163},{"nctId":"NCT04251819","phase":"PHASE2, PHASE3","title":"Buprenorphine Plus Baclofen to Increase Analgesia in Healthy Volunteers","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2021-01-21","conditions":"Acute Pain, Analgesia","enrollment":19},{"nctId":"NCT07314346","phase":"PHASE1","title":"Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone","status":"NOT_YET_RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-12","conditions":"Healthy Volunteer Study","enrollment":32},{"nctId":"NCT06023459","phase":"PHASE3","title":"Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yih-Ing Hser","startDate":"2024-10-14","conditions":"Opioid-Related Disorders, Substance-Related Disorders, Narcotic-Related Disorders","enrollment":144},{"nctId":"NCT07296770","phase":"PHASE3","title":"An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain Service","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-05-01","conditions":"Postsurgical Pain Management, Postsurgical Pain, Chronic, Opioid Use After Surgery","enrollment":126},{"nctId":"NCT06130501","phase":"NA","title":"tAN for PTSD and OUD in Buprenorphine Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cincinnati","startDate":"2024-07-01","conditions":"Posttraumatic Stress Disorder, Opioid Use Disorder","enrollment":20},{"nctId":"NCT06027814","phase":"NA","title":"MHealth Incentivized Adherence Plus Patient Navigation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2024-01-03","conditions":"Opioid Use Disorder, Medication Adherence, Polysubstance Drug Use (Indiscriminate Drug Use)","enrollment":40},{"nctId":"NCT04464980","phase":"PHASE2","title":"Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2021-06-08","conditions":"Opioid Use Disorder (OUD)","enrollment":1516},{"nctId":"NCT03150173","phase":"PHASE2","title":"Onsite Buprenorphine Treatment at Syringe Exchange Programs","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2019-01-02","conditions":"Opiate Addiction","enrollment":97},{"nctId":"NCT04345718","phase":"PHASE2, PHASE3","title":"EXHIT ENTRE Comparative Effectiveness Trial","status":"COMPLETED","sponsor":"Gavin Bart","startDate":"2021-08-09","conditions":"Substance Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe","enrollment":344},{"nctId":"NCT04464421","phase":"NA","title":"SMART Effectiveness Trial","status":"COMPLETED","sponsor":"Karen Derefinko, PhD","startDate":"2020-08-17","conditions":"Opioid-use Disorder, Opioid Dependence, Treatment Adherence","enrollment":48},{"nctId":"NCT06593353","phase":"NA","title":"Systems Analysis and Improvement to Optimize Opioid Use Disorder Care Quality and Continuity for Patients Exiting Jail","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-11-21","conditions":"Opioid Use Disorder, Opioid Use Disorders","enrollment":4165},{"nctId":"NCT07262190","phase":"NA","title":"NavSTAR Implementation Effectiveness Trial Across a Health System","status":"RECRUITING","sponsor":"Friends Research Institute, Inc.","startDate":"2025-10-27","conditions":"Opioid Use Disorder","enrollment":720},{"nctId":"NCT06416020","phase":"NA","title":"Integrating MOUD in Nonmedical Community Settings (Better Together)","status":"NOT_YET_RECRUITING","sponsor":"Howard University","startDate":"2026-01-26","conditions":"Opioid Use Disorder","enrollment":400},{"nctId":"NCT07251283","phase":"NA","title":"Food Insecurity and Eating Behavior Among Adults Receiving Buprenorphine or Methadone Maintenance Treatment: Pilot Study 2","status":"RECRUITING","sponsor":"University of Vermont","startDate":"2025-11-07","conditions":"Food Security","enrollment":40},{"nctId":"NCT06999811","phase":"NA","title":"Technology-Enhanced Therapy vs. Medication Monitoring for Buprenorphine Retention in Pregnant Persons","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2025-11-05","conditions":"Opioid Use Disorder, Pregnancy","enrollment":37},{"nctId":"NCT05270434","phase":"NA","title":"Optimal Timing of Endoscopic Intervention in the Treatment of Chronic Pancreatitis.","status":"COMPLETED","sponsor":"Changhai Hospital","startDate":"2025-03-12","conditions":"Pancreatitis, Chronic","enrollment":220},{"nctId":"NCT06774248","phase":"NA","title":"Expanding the Youth Opioid Recovery Support (YORS) Intervention for MOUD Adherence to Adolescents With OUD","status":"RECRUITING","sponsor":"Potomac Health Foundations","startDate":"2025-02-01","conditions":"Opioid Use Disorder","enrollment":80},{"nctId":"NCT06442566","phase":"PHASE1, PHASE2","title":"ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2024-08-12","conditions":"Opioid Withdrawal, Chronic Pain","enrollment":240},{"nctId":"NCT06574009","phase":"PHASE4","title":"Better Options for Chronic Cancer Pain","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2025-10-07","conditions":"Chronic Pain, Cancer Survivor, Opioid Dependence","enrollment":294},{"nctId":"NCT06732596","phase":"NA","title":"Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents","status":"RECRUITING","sponsor":"Boston Medical Center","startDate":"2025-10-30","conditions":"Opioid Use Disorder","enrollment":100},{"nctId":"NCT05118204","phase":"PHASE4","title":"Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization","status":"TERMINATED","sponsor":"Montefiore Medical Center","startDate":"2022-09-29","conditions":"Substance Use Disorders, Opioid-use Disorder, Chronic Pain","enrollment":23},{"nctId":"NCT05339256","phase":"PHASE2","title":"Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual","status":"NOT_YET_RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2026-02-01","conditions":"Opioid Use Disorder","enrollment":50},{"nctId":"NCT06323824","phase":"PHASE4","title":"Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment.","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-06-04","conditions":"Opioid Use Disorder","enrollment":600},{"nctId":"NCT06316830","phase":"PHASE2, PHASE3","title":"Identifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose","status":"RECRUITING","sponsor":"Rhode Island Hospital","startDate":"2025-01-06","conditions":"Opioid Use Disorder","enrollment":250},{"nctId":"NCT06384781","phase":"NA","title":"STAMPS: South Carolina Buprenorphine Treatment Initiation, Adherence, and Retention Utilizing Mobile Health Units and Peer Support Specialists","status":"COMPLETED","sponsor":"Prisma Health-Upstate","startDate":"2024-05-02","conditions":"Opioid Use Disorder","enrollment":90},{"nctId":"NCT06086275","phase":"PHASE1","title":"Oral Buprenorphine as a Novel Low-dose Induction Strategy for Opioid Use Disorder","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2024-06-04","conditions":"Opioid Use Disorder","enrollment":18},{"nctId":"NCT05589181","phase":"PHASE3","title":"High Dose Buprenorphine (BUP) Induction in the Emergency Department (ED)","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2023-04-06","conditions":"Opioid Use Disorder","enrollment":140},{"nctId":"NCT06961058","phase":"NA","title":"Telehealth vs In-Person Evaluation of Addiction Treatment After Visiting the Emergency Department","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2025-06-03","conditions":"Opioid Use Disorder","enrollment":528},{"nctId":"NCT05262270","phase":"PHASE2","title":"Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2023-04-18","conditions":"Cocaine Use Disorder","enrollment":427},{"nctId":"NCT05711056","phase":"NA","title":"Rural Expanded Access to OUD Care & Linkage Using Toxicologists for Telehealth Initiated Treatment","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-08-30","conditions":"Opioid Use, Opioid Abuse","enrollment":480},{"nctId":"NCT06521476","phase":"PHASE2","title":"Acetazolamide in Central Sleep Apnea Patients Using Medication for Opioid Use Disorder","status":"RECRUITING","sponsor":"Sanjay R Patel","startDate":"2025-09-30","conditions":"Central Sleep Apnea Comorbid With Opioid Use","enrollment":40},{"nctId":"NCT04161066","phase":"PHASE1","title":"Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2021-01-13","conditions":"Opioid Use Disorder","enrollment":10},{"nctId":"NCT05790252","phase":"PHASE3","title":"Transdermal Patch for BupRenorphine Induction DurinG PrEgnancy (Patch BRIDGE)","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-11-27","conditions":"Opioid Use Disorder, Pregnancy Related, Pregnancy, High Risk","enrollment":40},{"nctId":"NCT07214389","phase":"NA","title":"PRoducing Outcome Measures for OTP Quality Improvement","status":"NOT_YET_RECRUITING","sponsor":"RTI International","startDate":"2025-10-03","conditions":"Opioid Use Disorder","enrollment":4500},{"nctId":"NCT04600414","phase":"NA","title":"Collaborating to Heal Addiction and Mental Health in Primary Care","status":"COMPLETED","sponsor":"University of Washington","startDate":"2020-11-16","conditions":"Opioid-use Disorder, Mental Health Disorder","enrollment":254},{"nctId":"NCT06855732","phase":"NA","title":"Pain Self-Management and Treatment Engagement for Patients Taking Opioids","status":"RECRUITING","sponsor":"University of Pittsburgh","startDate":"2024-11-25","conditions":"Chronic Pain, Opioid Use Disorder, Opioid Misuse and Addiction","enrollment":204},{"nctId":"NCT07202039","phase":"NA","title":"Electronic Cigarettes as a Harm Reduction Strategy Among People With Opioid Use Disorder on Buprenorphine","status":"NOT_YET_RECRUITING","sponsor":"Prisma Health-Upstate","startDate":"2026-01-05","conditions":"Tobacco-flavored EC, Sweet-Cooling EC, Sweet Non-cooling EC","enrollment":90},{"nctId":"NCT04811014","phase":"PHASE4","title":"Young Houston Emergency Opioid Engagement System","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2021-04-19","conditions":"Opioid-use Disorder, Opioid Dependence, Opioid Overdose","enrollment":250},{"nctId":"NCT03396276","phase":"PHASE4","title":"Houston Emergency Opioid Engagement System","status":"ENROLLING_BY_INVITATION","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2018-04-01","conditions":"Opioid Use Disorder","enrollment":3000},{"nctId":"NCT06639464","phase":"PHASE2","title":"Semaglutide for Helping Opioid Recovery","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2025-06-02","conditions":"Opioid Use Disorder","enrollment":46},{"nctId":"NCT05450718","phase":"PHASE4","title":"Low-dose Buprenorphine Initiation for Opioid Use Disorder","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2024-11-11","conditions":"Opioid Use Disorder","enrollment":70},{"nctId":"NCT07169409","phase":"PHASE1","title":"Right Tools, Right Time, Right Place: Telehealth for Opioid Use Disorder in Vulnerable Settings","status":"RECRUITING","sponsor":"Boulder Care","startDate":"2025-06-10","conditions":"Opioid Use Disorder","enrollment":250},{"nctId":"NCT06051890","phase":"PHASE4","title":"Assessing Optimal XRB Initiation Points in Jail","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-06-02","conditions":"Opioid Use Disorder","enrollment":200},{"nctId":"NCT05288751","phase":"NA","title":"Contingency Management for Opioid and Stimulant Use Disorders in Primary Care","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Minnesota","startDate":"2022-06-15","conditions":"Opioid Use Disorder, Stimulant Use Disorder","enrollment":56},{"nctId":"NCT06379984","phase":"PHASE2","title":"Rapid Outpatient Low-dose Initiation of Buprenorphine for OUD With Fentanyl Use","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-05-08","conditions":"Opioid Use Disorder","enrollment":60},{"nctId":"NCT03646058","phase":"PHASE3","title":"Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2021-10-10","conditions":"Suicidal Ideation, Major Depressive Episode","enrollment":180},{"nctId":"NCT05122676","phase":"NA","title":"More Individualized Care: Assessment and Recovery Through Engagement","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kaiser Permanente","startDate":"2021-11-10","conditions":"Depression, Anxiety, Opioid-Related Disorders","enrollment":805},{"nctId":"NCT05944952","phase":"PHASE4","title":"Low-dose Versus a High-dose Sublingual Buprenorphine Induction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Friends Research Institute, Inc.","startDate":"2024-06-20","conditions":"Opioid Use Disorder","enrollment":40},{"nctId":"NCT06569667","phase":"NA","title":"Using AI and Peer Coaching to Address Racial Disparities Among People Who Use Opioids","status":"RECRUITING","sponsor":"Friends Research Institute, Inc.","startDate":"2025-03-28","conditions":"Opioid Use Disorder","enrollment":292},{"nctId":"NCT05145764","phase":"PHASE2","title":"Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2022-03-30","conditions":"Suvorexant, Placebo, Opioid Use Disorder","enrollment":120},{"nctId":"NCT06642181","phase":"PHASE1","title":"Combined Guanfacine and Mindfulness Meditation as an Adjunct to Buprenorphine Maintenance in Opioid Use Disorder","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2025-07-15","conditions":"Mindfulness, Guanfacine, Opioid Use Disorder","enrollment":224}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Buprenorphine (Experimental)","genericName":"Buprenorphine (Experimental)","companyName":"University of Alabama at Birmingham","companyId":"university-of-alabama-at-birmingham","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the central nervous system, producing analgesia and reducing opioid cravings. Used for Moderate to severe acute and chronic pain, Opioid use disorder (maintenance treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}